NCT00518570

Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder (PMDD)

A Pilot Study: Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Berkshire Health Systems · Academic / Other
• Sex: Female
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the clinical efficacy of Levetiracetam in the treatment of symptoms of premenstrual dysphoric disorder (PMDD) in an open label study.

Conditions

• Premenstrual Dysphoric Disorder

Interventions

Type	Name	Description
DRUG	Levetiracetam	Levetiracetam was started at 250 mg qhs at the end of the first week of the follicular phase. Dose was gradually increased up to 1500 mg bid as tolerated or clinically effective. The treatment phase lasted 4 months.

Timeline

• Start date: 2003-11-01
• Completion: 2006-10-01
• First posted: 2007-08-20
• Last updated: 2007-08-20

Locations

1 site across 1 country: United States